Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Drug

Jiangsu Hengrui Receives NMPA Approval to Begin Clinical Trials for New Anticancer Biologic

Fineline Cube Jun 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Shenzhen Light and Biotechnology Partners with Shenzhen Increcare Biotech in IVD Sector

Fineline Cube Jun 5, 2024

Shenzhen Light and Biotechnology Co., Ltd, a company based in China, has entered into a...

Company Drug

AIM Vaccine Submits Pre-IND Applications for mRNA Vaccines Targeting RSV and Herpes Zoster to NMPA

Fineline Cube Jun 5, 2024

AIM Vaccine Co., Ltd (HKG: 6660), a biopharmaceutical company based in China, has announced the...

Company Deals

OBiO Technology Partners with Shenzhen Innovation Immunotechnology for TCR-T Cell Therapy Development

Fineline Cube Jun 5, 2024

OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading Contract Research Organization (CRO) specializing in...

Company Drug

Olymvax Bio Receives Ethical Approval for Oral Helicobacter pylori Vaccine Trial in Australia

Fineline Cube Jun 5, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...

Company Drug

Sanofi Receives NMPA Approval for Phase III Clinical Trial of RSV Vaccine SP0125

Fineline Cube Jun 5, 2024

Sanofi (EPA: SAN), a major French multinational pharmaceutical company, has announced that it has received...

Company Deals Medical Device

BOE-Backed Genewise Bio Secures RMB 100 Million in Series A Financing for Molecular Diagnostics

Fineline Cube Jun 5, 2024

Genewise Bio, a molecular diagnostics company nurtured by BOE Technology Group, has reportedly secured RMB...

Company Drug

Huadong Medicine’s ROR1-Targeting ADC HDM2005 Cleared for Clinical Trials by China’s NMPA

Fineline Cube Jun 5, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a biopharmaceutical company based in China, has announced that...

Hospital Policy / Regulatory

China’s NHC Mandates Urban Hospitals to Aid County-Level Medical Institutions

Fineline Cube Jun 5, 2024

The National Health Commission (NHC) has issued a notification aimed at further promoting the allocation...

Company Drug

Gilead and Arcus Biosciences Report Positive Combination Therapy Results in mCRC Trial

Fineline Cube Jun 5, 2024

Biopharmaceutical companies Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced safety and efficacy...

Company Drug

AstraZeneca’s Tagrisso Achieves Milestone Progression-Free Survival in Late-Stage Lung Cancer Study

Fineline Cube Jun 5, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has announced preliminary results from...

Company Drug

MicuRx Pharmaceuticals’ MRX-8 Achieves Positive Results in Phase I Clinical Study

Fineline Cube Jun 5, 2024

MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has announced the successful completion...

Company Deals

Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute

Fineline Cube Jun 5, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, has announced that its subsidiary,...

Company Deals

Eli Lilly Acquires QurAlis’ UNC13A-Targeting Compounds for Neurodegenerative Diseases

Fineline Cube Jun 5, 2024

Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization...

Company Drug

Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Recommended for Approval by EMA’s CHMP

Fineline Cube Jun 4, 2024

Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company based in Guangzhou, has received notification that the...

Company Medical Device

Zylox-Tonbridge Medical Technology Earns NMPA Approval for First Vascular Stapler in China

Fineline Cube Jun 4, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...

Company Deals Drug

Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody

Fineline Cube Jun 4, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing...

Company Drug

Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs

Fineline Cube Jun 4, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...

Company

China Meheco Group Appoints Yang Guang as Chairman and Legal Representative

Fineline Cube Jun 4, 2024

China Meheco Group Co., Ltd (SHA: 600056) has announced the appointment of Yang Guang to...

Company Drug

Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China

Fineline Cube Jun 4, 2024

Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval...

Posts pagination

1 … 393 394 395 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.